Skip to main content
Top
Published in: AIDS and Behavior 12/2020

01-12-2020 | Antidepressant Drugs | Original Paper

Improvements in Retention in Care and HIV Viral Suppression Among Persons with HIV and Comorbid Mental Health Conditions: Patient-Centered HIV Care Model

Authors: Kathy K. Byrd, Felicia Hardnett, John G. Hou, Patrick G. Clay, Sumihiro Suzuki, Nasima M. Camp, Michael D. Shankle, Paul J. Weidle, Michael S. Taitel, the Patient-Centered HIV Care Model Team

Published in: AIDS and Behavior | Issue 12/2020

Login to get access

Abstract

The Patient-centered HIV Care Model (PCHCM) integrated community-based pharmacists with medical providers and required sharing of patient clinical information and collaborative therapy-related action planning. We determined the proportions of participants with HIV and mental health conditions who were retained in care and the proportion virally suppressed, pre- and post-implementation. Overall, we found a relative 13% improvement in both retention [60% to 68% (p = 0.009)] and viral suppression [79% to 90% (p < 0.001)]. Notable improvements were seen among persons triply diagnosed with HIV, mental illness and substance use [+ 36% (50% to 68%, p = 0.036) and + 32% (66% to 86%, p = 0.001) in retention and viral suppression, respectively]. There were no differences in the proportions of persons adherent to psychiatric medications, pre- to post-implementation, nor were there differences in the proportions of persons retained in care or virally suppressed by psychiatric medication adherence, post-implementation. PCHCM demonstrated that collaborations between community-based pharmacists and medical providers can improve HIV care continuum outcomes among persons with mental health conditions.
Literature
1.
go back to reference Tegger MK, Crane HM, Tapia KA, et al. The effect of mental illness, substance use, and treatment for depression on the initiation of highly active antiretroviral therapy among HIV-infected individuals. AIDS Patient Care STDS. 2008;22(3):233–43.CrossRef Tegger MK, Crane HM, Tapia KA, et al. The effect of mental illness, substance use, and treatment for depression on the initiation of highly active antiretroviral therapy among HIV-infected individuals. AIDS Patient Care STDS. 2008;22(3):233–43.CrossRef
2.
go back to reference Kessler RC, Demler O, Frank RG, et al. Prevalence and treatment of mental disorders, 1990 to 2003. N Engl J Med. 2005;352(24):2515–23.CrossRef Kessler RC, Demler O, Frank RG, et al. Prevalence and treatment of mental disorders, 1990 to 2003. N Engl J Med. 2005;352(24):2515–23.CrossRef
3.
go back to reference Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry. 2001;58(8):721–8.CrossRef Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry. 2001;58(8):721–8.CrossRef
4.
go back to reference Nanni MG, Caruso R, Mitchell AJ, et al. Depression in HIV infected patients: a review. Curr Psychiatry Rep. 2015;17(1):530.CrossRef Nanni MG, Caruso R, Mitchell AJ, et al. Depression in HIV infected patients: a review. Curr Psychiatry Rep. 2015;17(1):530.CrossRef
5.
go back to reference Rooks-Peck CR, Adegbite AH, Wichser ME, et al. Mental health and retention in HIV care: a systematic review and meta-analysis. Health Psychol. 2018;37(6):574–85.CrossRef Rooks-Peck CR, Adegbite AH, Wichser ME, et al. Mental health and retention in HIV care: a systematic review and meta-analysis. Health Psychol. 2018;37(6):574–85.CrossRef
6.
go back to reference Gonzalez JS, Batchelder AW, Psaros C, et al. Depression and HIV/AIDS treatment nonadherence: a review and meta-analysis. J Acquir Immune Defic Syndr. 2011;58(2):181–7.CrossRef Gonzalez JS, Batchelder AW, Psaros C, et al. Depression and HIV/AIDS treatment nonadherence: a review and meta-analysis. J Acquir Immune Defic Syndr. 2011;58(2):181–7.CrossRef
7.
go back to reference Springer SA, Dushaj A, Azar MM. The impact of DSM-IV mental disorders on adherence to combination antiretroviral therapy among adult persons living with HIV/AIDS: a systematic review. AIDS Behav. 2012;16(8):2119–43.CrossRef Springer SA, Dushaj A, Azar MM. The impact of DSM-IV mental disorders on adherence to combination antiretroviral therapy among adult persons living with HIV/AIDS: a systematic review. AIDS Behav. 2012;16(8):2119–43.CrossRef
8.
go back to reference Pence BW, Miller WC, Gaynes BN, et al. Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2007;44(2):159–66.CrossRef Pence BW, Miller WC, Gaynes BN, et al. Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2007;44(2):159–66.CrossRef
9.
go back to reference Yehia BR, Stephens-Shield AJ, Momplaisir F, et al. Health outcomes of HIV-infected people with mental illness. AIDS Behav. 2015;19(8):1491–500.CrossRef Yehia BR, Stephens-Shield AJ, Momplaisir F, et al. Health outcomes of HIV-infected people with mental illness. AIDS Behav. 2015;19(8):1491–500.CrossRef
10.
go back to reference Pence BW, Mills JC, Bengtson AM, et al. Association of increased chronicity of depression with HIV appointment attendance, treatment failure, and mortality among HIV-infected adults in the United States. JAMA Psychiatry. 2018;75(4):379–85.CrossRef Pence BW, Mills JC, Bengtson AM, et al. Association of increased chronicity of depression with HIV appointment attendance, treatment failure, and mortality among HIV-infected adults in the United States. JAMA Psychiatry. 2018;75(4):379–85.CrossRef
11.
go back to reference Remien RH, Stirratt MJ, Nguyen N, et al. Mental health and HIV/AIDS: the need for an integrated response. AIDS. 2019;33(9):1411–20.CrossRef Remien RH, Stirratt MJ, Nguyen N, et al. Mental health and HIV/AIDS: the need for an integrated response. AIDS. 2019;33(9):1411–20.CrossRef
12.
go back to reference Helleberg M, Pedersen MG, Pedersen CB, et al. Associations between HIV and schizophrenia and their effect on HIV treatment outcomes: a nationwide population-based cohort study in Denmark. Lancet HIV. 2015;2(8):e344–50.CrossRef Helleberg M, Pedersen MG, Pedersen CB, et al. Associations between HIV and schizophrenia and their effect on HIV treatment outcomes: a nationwide population-based cohort study in Denmark. Lancet HIV. 2015;2(8):e344–50.CrossRef
13.
go back to reference Hartzler B, Dombrowski JC, Crane HM, et al. Prevalence and predictors of substance use disorders among HIV care enrollees in the United States. AIDS Behav. 2017;21(4):1138–48.CrossRef Hartzler B, Dombrowski JC, Crane HM, et al. Prevalence and predictors of substance use disorders among HIV care enrollees in the United States. AIDS Behav. 2017;21(4):1138–48.CrossRef
14.
go back to reference Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. The NSDUH report: HIV/AIDS and substance use. Rockville: Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality; 2010. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. The NSDUH report: HIV/AIDS and substance use. Rockville: Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality; 2010.
15.
go back to reference Nolan S, Walley AY, Heeren TC, et al. HIV-infected individuals who use alcohol and other drugs, and virologic suppression. AIDS Care. 2017;29(9):1129–36.CrossRef Nolan S, Walley AY, Heeren TC, et al. HIV-infected individuals who use alcohol and other drugs, and virologic suppression. AIDS Care. 2017;29(9):1129–36.CrossRef
16.
go back to reference Hartzler B, Dombrowski JC, Williams JR, et al. Influence of substance use disorders on 2-year HIV care retention in the United States. AIDS Behav. 2018;22(3):742–51.CrossRef Hartzler B, Dombrowski JC, Williams JR, et al. Influence of substance use disorders on 2-year HIV care retention in the United States. AIDS Behav. 2018;22(3):742–51.CrossRef
17.
go back to reference Biello KB, Oldenburg CE, Safren SA, et al. Multiple syndemic psychosocial factors are associated with reduced engagement in HIV care among a multinational, online sample of HIV-infected MSM in Latin America. AIDS Care. 2016;28(Suppl 1):84–91.CrossRef Biello KB, Oldenburg CE, Safren SA, et al. Multiple syndemic psychosocial factors are associated with reduced engagement in HIV care among a multinational, online sample of HIV-infected MSM in Latin America. AIDS Care. 2016;28(Suppl 1):84–91.CrossRef
18.
go back to reference Blashill AJ, Bedoya CA, Mayer KH, et al. Psychosocial syndemics are additively associated with worse ART adherence in HIV-infected individuals. AIDS Behav. 2015;19(6):981–6.CrossRef Blashill AJ, Bedoya CA, Mayer KH, et al. Psychosocial syndemics are additively associated with worse ART adherence in HIV-infected individuals. AIDS Behav. 2015;19(6):981–6.CrossRef
19.
go back to reference Friedman MR, Stall R, Silvestre AJ, et al. Effects of syndemics on HIV viral load and medication adherence in the Multicentre AIDS Cohort Study. AIDS. 2015;29(9):1087–96.CrossRef Friedman MR, Stall R, Silvestre AJ, et al. Effects of syndemics on HIV viral load and medication adherence in the Multicentre AIDS Cohort Study. AIDS. 2015;29(9):1087–96.CrossRef
20.
go back to reference Glynn TR, Safren SA, Carrico AW, et al. High levels of syndemics and their association with adherence, viral non-suppression, and biobehavioral transmission risk in Miami, a U.S. City with an HIV/AIDS epidemic. AIDS Behav. 2019;23(11):2956–65.CrossRef Glynn TR, Safren SA, Carrico AW, et al. High levels of syndemics and their association with adherence, viral non-suppression, and biobehavioral transmission risk in Miami, a U.S. City with an HIV/AIDS epidemic. AIDS Behav. 2019;23(11):2956–65.CrossRef
21.
go back to reference Harkness A, Bainter SA, O’Cleirigh C, et al. Longitudinal effects of syndemics on ART non-adherence among sexual minority men. AIDS Behav. 2018;22(8):2564–74.CrossRef Harkness A, Bainter SA, O’Cleirigh C, et al. Longitudinal effects of syndemics on ART non-adherence among sexual minority men. AIDS Behav. 2018;22(8):2564–74.CrossRef
22.
go back to reference Mizuno Y, Purcell DW, Knowlton AR, et al. Syndemic vulnerability, sexual and injection risk behaviors, and HIV continuum of care outcomes in HIV-positive injection drug users. AIDS Behav. 2015;19(4):684–93.CrossRef Mizuno Y, Purcell DW, Knowlton AR, et al. Syndemic vulnerability, sexual and injection risk behaviors, and HIV continuum of care outcomes in HIV-positive injection drug users. AIDS Behav. 2015;19(4):684–93.CrossRef
23.
go back to reference Byrd KK, Hardnett F, Clay PG, et al. Retention in HIV care among participants in the Patient-centered HIV Care Model: a collaboration between community-based pharmacists and primary medical providers. AIDS Patient Care STDS. 2019;33(2):58–66.CrossRef Byrd KK, Hardnett F, Clay PG, et al. Retention in HIV care among participants in the Patient-centered HIV Care Model: a collaboration between community-based pharmacists and primary medical providers. AIDS Patient Care STDS. 2019;33(2):58–66.CrossRef
24.
go back to reference Byrd KK, Hou JG, Bush T, et al. Adherence and viral suppression among participants of the Patient-centered HIV Care Model project—a collaboration between community-based pharmacists and HIV clinical providers. Clin Infect Dis. 2020;70(5):789–97.PubMed Byrd KK, Hou JG, Bush T, et al. Adherence and viral suppression among participants of the Patient-centered HIV Care Model project—a collaboration between community-based pharmacists and HIV clinical providers. Clin Infect Dis. 2020;70(5):789–97.PubMed
25.
go back to reference American Pharmacists Association, National Association of Chain Drug Stores Foundation. Medication therapy management in pharmacy practice: core elements of an MTM service model (version 2.0). J Am Pharm Assoc (2003). 2008;48:341–53.CrossRef American Pharmacists Association, National Association of Chain Drug Stores Foundation. Medication therapy management in pharmacy practice: core elements of an MTM service model (version 2.0). J Am Pharm Assoc (2003). 2008;48:341–53.CrossRef
30.
go back to reference Günthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society-USA Panel. JAMA. 2016;316(2):191–21010.CrossRef Günthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society-USA Panel. JAMA. 2016;316(2):191–21010.CrossRef
34.
go back to reference Durvasula R, Miller TR. Substance abuse treatment in persons with HIV/AIDS: challenges in managing triple diagnosis. Behav Med. 2014;40(2):43–52.CrossRef Durvasula R, Miller TR. Substance abuse treatment in persons with HIV/AIDS: challenges in managing triple diagnosis. Behav Med. 2014;40(2):43–52.CrossRef
35.
go back to reference Chander G, Himelhoch S, Fleishman JA, et al. HAART receipt and viral suppression among HIV-infected patients with co-occurring mental illness and illicit drug use. AIDS Care. 2009;21(5):655–63.CrossRef Chander G, Himelhoch S, Fleishman JA, et al. HAART receipt and viral suppression among HIV-infected patients with co-occurring mental illness and illicit drug use. AIDS Care. 2009;21(5):655–63.CrossRef
36.
go back to reference Yellin H, Beckwith C, Kurth A, et al. Syndemic effect of mental illness and substance use on viral suppression among recently-incarcerated, HIV-infected individuals in the CARE+ corrections study. AIDS Care. 2018;30(10):1252–6.CrossRef Yellin H, Beckwith C, Kurth A, et al. Syndemic effect of mental illness and substance use on viral suppression among recently-incarcerated, HIV-infected individuals in the CARE+ corrections study. AIDS Care. 2018;30(10):1252–6.CrossRef
37.
go back to reference Cranston K, Alpren C, John B, et al. Notes from the field: HIV diagnoses among persons who inject drugs—northeastern Massachusetts, 2015–2018. Morb Mortal Wkly Rep. 2019;68(10):253–4.CrossRef Cranston K, Alpren C, John B, et al. Notes from the field: HIV diagnoses among persons who inject drugs—northeastern Massachusetts, 2015–2018. Morb Mortal Wkly Rep. 2019;68(10):253–4.CrossRef
38.
go back to reference Golden MR, Lechtenberg R, Glick SN, et al. Outbreak of human immunodeficiency virus infection among heterosexual persons who are living homeless and inject drugs—Seattle, Washington, 2018. Morb Mortal Wkly Rep. 2019;68(15):344–9.CrossRef Golden MR, Lechtenberg R, Glick SN, et al. Outbreak of human immunodeficiency virus infection among heterosexual persons who are living homeless and inject drugs—Seattle, Washington, 2018. Morb Mortal Wkly Rep. 2019;68(15):344–9.CrossRef
39.
go back to reference Peters PJ, Pontones P, Hoover KW, et al. HIV infection linked to injection use of oxymorphone in Indiana, 2014–2015. N Engl J Med. 2016;375(3):229–39.CrossRef Peters PJ, Pontones P, Hoover KW, et al. HIV infection linked to injection use of oxymorphone in Indiana, 2014–2015. N Engl J Med. 2016;375(3):229–39.CrossRef
40.
go back to reference Mugavero MJ, Lin HY, Willig JH, et al. Missed visits and mortality among patients establishing initial outpatient HIV treatment. Clin Infect Dis. 2009;48(2):248–56.CrossRef Mugavero MJ, Lin HY, Willig JH, et al. Missed visits and mortality among patients establishing initial outpatient HIV treatment. Clin Infect Dis. 2009;48(2):248–56.CrossRef
41.
go back to reference Hall HI, Gray KM, Tang T, et al. Retention in care of adults and adolescents living with HIV in 13 U.S. areas. J Acquir Immune Defic Syndr. 2012;60(1):77–82.CrossRef Hall HI, Gray KM, Tang T, et al. Retention in care of adults and adolescents living with HIV in 13 U.S. areas. J Acquir Immune Defic Syndr. 2012;60(1):77–82.CrossRef
Metadata
Title
Improvements in Retention in Care and HIV Viral Suppression Among Persons with HIV and Comorbid Mental Health Conditions: Patient-Centered HIV Care Model
Authors
Kathy K. Byrd
Felicia Hardnett
John G. Hou
Patrick G. Clay
Sumihiro Suzuki
Nasima M. Camp
Michael D. Shankle
Paul J. Weidle
Michael S. Taitel
the Patient-Centered HIV Care Model Team
Publication date
01-12-2020
Publisher
Springer US
Published in
AIDS and Behavior / Issue 12/2020
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-020-02913-2

Other articles of this Issue 12/2020

AIDS and Behavior 12/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.